SUMMARY

Transcell Oncologics as a spin-out from its original company, is a pioneering biotech firm focused on oncology drug discovery using adult stem cell technology. Its mission is to identify novel, first-in-class molecules targeting challenging cancer-related proteins and leverage its proprietary progenitor cell platform technology for ethically compliant in vitro human physiological models. Key Areas of Focus: Discovery of Druggable Molecules: Transcell's primary goal is to find molecules that can selectively eliminate cancer stem cells responsible for cancer relapse and metastasis. Patient-Derived Platforms: The company employs patient-derived cancer stem cell platforms to design targeted killing assays for drug discovery. Nature-Inspired Small Molecules: A significant part of their research involves creating a toolbox of complex macrocyclic small molecules inspired by nature. Phenotypic Drug Discovery: Transcell emphasizes phenotypic screens in drug discovery, an approach that focuses on observing cellular changes rather than targeting specific genes or proteins. Innovative Approaches: Cancer Stem Cell Targeting: Transcell is developing techniques to isolate tumor-specific cancer stem cells for various cancers, including brain, breast, colon, and prostate tumors. Drug Pipeline Development: The company has introduced 11 first-in-class candidates for Head & Neck and Colon cancers into its pipeline. Storage and Processing of Samples: Transcell has a repository for patient and donor-derived cells and xenografts, aiding their oncology research programs. Transcell Oncologics differentiates itself with its focus on patient-derived stem cell technologies, innovative drug discovery strategies targeting cancer stem cells, and its collaborative approach to research. The company aims to bridge the gap in oncology drug development, focusing on targeted therapies for solid tumors and metastasis prevention.

PRODUCTS

Human Surrogate In Vitro Systems (HuSu), HEMATO (for practicing Hemato-oncologists)

SERVICES

In-house R&D for drug discovery, focusing on solid tumors and utilizing patient-derived primary screens for specific tumor types. A unique repository of patient and donor sterile tissue/derived cells, progenitor cell populations, and xenografts, used for drug discovery and research programs in oncology, and offering collection, characterization, and distribution services

FOUNDER DETAILS

ABOUT

Transcell Oncologics aims to revolutionize cancer treatment by leveraging adult stem cell technology. Their mission is to discover unique, first-in-class molecules targeting hard-to-treat cancers, utilize proprietary cellular platforms mimicking human physiology for ethical research, and develop off-shelf vector technology for CAR-T cell therapies.

COMPANY TYPE

SERVICE VERTICALS

• Research Solutions

TECHNOLOGY

• Genomics
• Wet-Lab
• Analytics

THERAPEUTIC AREAS

• Oncology
• Hematology

VALUE OFFERING

• Research
• Diagnosis
• Treatment

LOCATION

Flat No. G1,G2, Plot No. 03 & 34, Prasantha Enclave, Vasavi Layout, Pragathi Nagar, Hyderabad, Telangana, India 500090

TARGET USERS

• HCP (Health Care Providers)
• Patients
• Corporate

INCORPORATION DATE

02 August 2017

STATE/CITY

Hyderabad, Telangana